Abstract
During photodynamic therapy (PDT) it is important to monitor the treatment progress to achieve the intended therapeutic outcome. Chemiluminescence (CL) provides a sensitive and selective means for 1O2 detection. In our study, by comparing CL with the corresponding in situ PDT treatment protocols and the treatment effect, the results indicate that the treatment outcome for tumors was governed by a set of dosimetry factors with a rather complicated relationship, but there was a remarkable connection between tumor treatment effect and CL. In conclusion, CL can be used in in vivo PDT to determine the dose of tumor treatment and monitor the treatment threshold. By monitoring CL it is feasible to determine PDT dose to predict tumor treatment effect.
Similar content being viewed by others
Notes and references
N. L. Oleinick, R. L. Morris and I. Belichenko, The role of apoptosis in response to photodynamic therapy: what, where, why, and how, Photochem. Photobiol. Sci., 2002, 1, 1–21.
C. W. McAndrew, R. F. Gastwirt and D. J. Donoghue, The atypical CDK activator Spy1 regulates the intrinsic DNA damage response and is dependent upon p53 to inhibit apoptosis, Cell Cycle, 2009, 8, 66–75.
F. F. Zhou, D. Xing and W. R. Chen, Dynamics and mechanism of HSP70 translocation induced by photodynamic therapy treatment, Cancer Lett., 2008, 264, 135–144.
S. N. Wu, D. Xing, F. Wang, T. S. Chen and W. R. Chen, Mechanistic study of apoptosis induced by high-fluence low-power laser irradiation using fluorescence imaging techniques, J. Biomed. Opt., 2007, 12, 064015.
X. J. Gao, T. S. Chen, D. Xing, F. Wang, Y. H. Pei and X. B. Wei, Single cell analysis of PKC activation during proliferation and apoptosis induced by laser irradiation, J. Cell. Physiol., 2006, 206, 441–448.
S. B. Brown, E. A. Brown and I. Walker, The present and future role of photodynamic therapy in cancer treatment, Lancet Oncol., 2004, 5, 497–508.
T. J. Farrell, B. C. Wilson, M. S. Patterson and M. C. Olivo, Comparison of the in vivo photodynamic threshold dose for photofrin, mono-and tetrasulfonated aluminium phthalocyanine using a rat liver model, Photochem. Photobiol., 1998, 68, 394–399.
M. S. Patterson, B. C. Wilson and R. Graff, In vivo tests of the concept of photodynamic threshold dose in normal rat liver photosensitized by aluminium chlorosulfonated phthalocyanine, Photochem. Photobiol., 1990, 51, 343–349.
I. A. Boere, D. J. Robinson, H. S. de Bruijn, J. van den Boogert, H. W. Tilanus, H. J. Sterenborg and R. W. de Bruin, Monitoring in situ dosimetry and protoporphyrin IX fluorescence photobleaching in the normal rat esophagus during 5-aminolevulinic acid photodynamic therapy, Photochem. Photobiol., 2003, 78, 271–277.
A. Johansson, T. Johansson, M. S. Thompson, N. Bendsoe, K. Svan-berg, S. Svanberg and S. Andersson-Engels, In vivo measurement of parameters of dosimetric importance during interstitial photodynamic therapy of thick skin tumors, J. Biomed. Opt., 2006, 11, 34029.
H. W. Wang, M. E. Putt, M. J. Emanuele, D. B. Shin, E. Glatstein, A. G. Yodh and T. M. Busch, Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome, Cancer Res., 2004, 64, 7553–7561.
L. Z. Xiang, D. Xing, H. M. Gu, D. W. Yang, S. H. Yang, L. M. Zeng and W. R. Chen, Real-time optoacoustic monitoring of vascular damage during photodynamic therapy treatment of tumor, J. Biomed. Opt., 2007, 12, 014001.
J. Yamamoto, S. Yamamoto, T. Hirano, S. Li, M. Koide, E. Kohno, M. Okada, C. Inenaga, T. Tokuyama, N. Yokota, S. Terakawa and H. Namba, Monitoring of singlet oxygen is useful for predicting the photodynamic effects in the treatment for experimental glioma, Clin. Cancer Res., 2006, 12, 7132–7139.
D. Trachootham, Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, H. Pelicano, P. J. Chiao, G. Achanta, R. B. Arlinghaus, J. Liu and P. Huang, Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate, Cancer Cell, 2006, 10, 241–252.
M. J. Niedre, C. S. Yu, M. S. Patterson and B. C. Wilson, Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid, Br. J. Cancer, 2005, 92, 298–304.
L. Y. Zang, Z. Y. Zhang and H. P. Misra, EPR studies of trapped singlet oxygen (1O2) generated during photoirradiation of hypocrellin A, Photochem. Photobiol., 1990, 52, 677–683.
M. T. Jarvi, M. J. Niedre, M. S. Patterson and B. C. Wilson, Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: current status, challenges and future prospects, Photochem. Photobiol., 2006, 82, 1198–1210.
Z. H. Song and C. N. Wang, Determination of picogram-levels of acetylspiramycin in human urine and serum by flow injection chemiluminescence, Microchim. Acta, 2004, 149, 117–122.
A. Hausladen, R. Rafikov, M. Angelo, D. J. Singel, E. Nudler and J. S. Stamler, Assessment of nitric oxide signals by triiodide chemiluminescence, Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 2157–2162.
J. Du, Y. Li and J. Lu, Flow injection chemiluminescence determination of captopril based on its enhancing effect on the luminolferricyanide/ferrocyanide reaction, Luminescence, 2002, 17, 165–167.
X. H. Li, G. X. Zhang, H. M. Ma, D. Q. Zhang, J. Li and D. B. Zhu, 4,5-Dimethylthio-4′-[2-(9-anthryloxy)ethylthio]tetrathiafulvalene, a highly selective and sensitive chemiluminescence probe for singlet oxygen, J. Am. Chem. Soc., 2004, 126, 11543–11548.
J. Wang, D. Xing, Y. G. He and X. J. Hu, Localization of tumor by chemiluminescence probe during photosensitization action, Cancer Lett., 2002, 188, 59–65.
Y. C. Wei, D. Xing, S. M. Luo, W. Xu and Q. Chen, Monitoring singlet oxygen in situ with delayed chemiluminescence to deduce the effect of photodynamic therapy, J. Biomed. Opt., 2008, 13, 024023.
Y. H. He, D. Xing, G. H. Yan and K. Ueda, FCLA chemiluminescence from sonodynamic action in vitro and in vivo, Cancer Lett., 2002, 182, 141–145.
S. Mashiko, N. Suzuki, S. Koga, M. Nakano, T. Goto, T. Ashino, I. Mizumoto and H. Inaba, Measurement of rate constants for quenching singlet oxygen with a Cypridina luciferin analog (2-methyl-6-[p-methoxyphenyl]-3,7-dihydroimidazo [1,2-a]pyrazin-3-one) and sodium azide, J. Biolumin. Chemilumin., 1991, 6, 69–72.
K. Teranishi and T. Nishiguchi, Cyclodextrin-bound 6-(4-methoxyphenyl)imidazo[1,2-alpha ±]pyrazin-3(7H)-ones with fluorescein as green chemiluminescent probes for superoxide anions, Anal. Biochem., 2004, 325, 185–195.
Y. X. Wu and D. Xing, Permeating eff iciency and localization of FCLA and HpD through Membrane of lung cancer cell, Acta Laser Biol. Sinica, 2005, 14, 287–292.
J. Wang, D. Xing, Y. H. He and X. J. Hu, Experimental study on photodynamic diagnosis of cancer mediated by chemiluminescence probe, FEBS Lett., 2002, 523, 128–132.
A. Jalili, M. Makowski, T. Switaj, D. Nowis, G. M. Wilczynski, E. Wilczek, M. Chorazy-Massalska, A. Radzikowska, W. Maslinski, L. Bialy, J. Sienko, A. Sieron, M. Adamek, G. Basak, P. Mroz, I. W. Krasnodebski, M. Jakobisiak and J. Golab, Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells, Clin. Cancer Res., 2004, 10, 4498–4508.
M. E. Murphy and H. Sies, Visible-range low-level chemiluminescence in biological systems, Methods Enzymol., 1990, 186, 595–610.
Y. C. Wei, D. Xing, S. M. Luo, L. Y. Yang and Q. Chen, Quantitative measurement of reactive oxygen species in vivo by utilizing a novel method: chemiluminescence with an internal fluorescence as reference, J. Biomed. Opt., 2010, 15, 027006.
K. M. Kurrelmeyer, L. H. Michael, G. Baumgarten, G. E. Taffet, J. J. Peschon, N. Sivasubramanian, M. L. Entman and D. L. Mann, Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction, Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5456–5461.
J. H. Woodhams, L. Kunz, S. G. Bown and A. J. MacRobert, Correlation of real-time haemoglobin oxygen saturation monitoring during photodynamic therapy with microvascular effects and tissue necrosis in normal rat liver, Br. J. Cancer, 2004, 91, 788–794.
M. Seshadri, D. A. Bellnier, L. A. Vaughan, J. A. Spernyak, R. Mazurchuk, T. H. Foster and B. W. Henderson, Light delivery over extended time periods enhances the effectiveness of photodynamic therapy, Clin. Cancer Res., 2008, 14, 2796–2805.
B. W. Henderson, S. O. Gollnick, J. W. Snyder, T. M. Busch, P. C. Kousis, R. T. Cheney and J. Morgan, Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors, Cancer Res., 2004, 64, 2120–2126.
R. Cheung, M. Solonenko, T. M. Busch, F. Del Piero, M. E. Putt, S. M. Hahn and A. G. Yodh, Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced depth of necrosis in a murine tumor model, J. Biomed. Opt., 2003, 8, 248–252.
Q. Chen, M. Chopp, L. Madigan, M. O. Dereski and F. W. Hetzel, Damage threshold of normal rat brain in photodynamic therapy, Photochem. Photobiol., 1996, 64, 163–167.
R. C. Ferraz, J. Ferreira, P. F. Menezes, C. H. Sibata, E. S. OC and V. S. Bagnato, Determination of threshold dose of photodynamic therapy to measure superficial necrosis, Photomed. Laser Surg., 2009, 27, 93–99.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wei, Y., Song, J. & Chen, Q. In vivo detection of chemiluminescence to monitor photodynamic threshold dose for tumor treatment. Photochem Photobiol Sci 10, 1066–1071 (2011). https://doi.org/10.1039/c0pp00346h
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1039/c0pp00346h